Erythropoietin in experimental acute renal failure

• Published in: Nephron. Experimental nephrology Vol. 104; no. 3; p. e83
• Main Authors: Sharples, E J, Yaqoob, M M
• Format: Journal Article
• Language: English
• Published: Switzerland 01-01-2006
• Subjects: Acute Kidney Injury - drug therapy; Animals; Cytoprotection; Endothelium, Vascular - drug effects; Endothelium, Vascular - physiopathology; Erythropoietin - therapeutic use; Kidney - blood supply; Reperfusion Injury - drug therapy; Reperfusion Injury - physiopathology
• ISSN: 1660-2129
• DOI: 10.1159/000094546

The haematopoietic factor erythropoietin (EPO) has recently been recognized to play a physiological role in the brain and other tissues. The EPO receptor is present in the glomerulus, mesangial and tubular epithelial cells in the kidney. We have reviewed the experimental use of EPO in animal models of acute renal failure. EPO attenuates the dysfunction and histological changes associated with ischaemia-reperfusion injury, with a reduction in apoptotic cell death. EPO has also shown benefit in animal models of systemic shock and cisplatin-induced nephrotoxicity. In vitro studies have shown that EPO has direct effects on proliferation and cell death in proximal tubular epithelial cells. There is increasingly strong experimental evidence that EPO may be of therapeutic use in acute renal failure, and clinical trials should be undertaken to determine its clinical applications in this field.